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Although heart transplantation (HT) and the implantation of a left ventricular assist device 
(LVAD) both provide clear benefits with respect to the natural history of advanced heart failure 
(HF), with 1‐year survival rates of around 80–90%,1, 2 many have had the impression that these 
advanced therapies are often underused – not just because of short supply or cost, but because of 
short demand, i.e. failure to refer suitable patients. This notion is supported by the fact that the 
frequency with which these therapies are employed varies not only from country to country3 
(Figure 1) but also among different regions of the same country, even when no causative 
significant differences in supply or cost are to be expected. For example, among the 17 Spanish 
autonomous communities, those two with the lowest HT rates do not have their own HT 
programmes (HT patients are referred to other communities), which suggests that the low rates 
may in part be due to a tendency to overlook the possibility of HT.4 Of course, it is also true that, 
for a number of reasons, including the subjectivity of many partial criteria of advanced HF, it is 





Figure 1. Heart transplantation rates in Europe in 2016 (patients per million population) according to the Global 
Observatory on Donation and Transplantation.3 ‘The data and information presented here are published in order to promote 
transparency in transplantation activities. They are the most reliable facts available to date to “Global Observatory on 
Donation and Transplantation” knowledge.’  
In this issue of the Journal, Lund and colleagues report the results of the ScrEEning for 
advanced Heart Failure treatment (SEE‐HF),5 a multicentre study in which a two‐stage screening 
protocol was applied to patients with a cardiac resynchronization therapy (CRT) or implantable 
cardioverter defibrillator (ICD) device to detect those who were eligible for HT or LVAD 
implantation. Eight centres in seven European countries participated, all of which had an LVAD 
programme and six of the eight an HT programme. The criterion for passage from stage 1 to stage 
2 of the screening protocol was that the patient was stable under optimal medical management, 
have New York Heart Association (NYHA) class III–IV HF symptoms and an ejection fraction 
(EF) ≤40%, and consent to undergo stage 2, i.e. further detailed work‐up for eligibility for HT and 
LVAD in accordance with the latest American and European guidelines.6-9 Patients meeting 
eligibility criteria were offered listing for HT or implantation of an LVAD. No randomization, 
blinding or control group were used.  
 
Of 1722 screened patients, 121 (7%) fulfilled the medical criteria, 99 of whom consented to 
further work‐up (5.7%). For 23 of the 99 (23%) HT or LVAD implantation was indicated without 
any contraindication, but the indicated intervention (listing for HT or LVAD implantation) was 
accepted by only 11 of these 23, i.e. 11% of those who had accepted further work‐up (three more 
were listed for HT or received an LVAD despite a guideline‐based contraindication).  
 
Although analysis of the results was limited by the unexpectedly small sample size 
(recruitment having been slow and consequently having been terminated before the desired sample 
size was reached), the authors of this innovative study are to be congratulated, for it has confirmed 
that active screening can find candidates for HT or LVAD implantation to whom these therapies 
would not otherwise have been offered at so early a date. In the present study, HT or LVAD 
implantation were offered to almost one‐quarter of the patients who progressed to stage 2 
screening, i.e. the consenting stable patients who had reduced EF and NYHA class III–IV 
symptoms as well as an implanted ICD or CRT. Although the yield of the first stage of the 
screening process was only 7% (as was to be expected, as many patients have an ICD or CRT to 
correct heart conditions that do not involve advanced HF), it would nevertheless seem amply to 
justify the relatively small effort of screening for reduced EF and NYHA class III–IV, given the 
high yield of the second stage and the clear prognostic benefit of HT and LVAD implantation.1, 2 
 
It would not seem to be reasonable to require stage 2 screening to be carried out in an ordinary 
CRT/ICD clinic. Rather, stage 2 screening should probably be performed in dedicated advanced 
HF units by cardiologists with specific training in the care of advanced HF patients, such as those 
who since 2008 have been recognized by the American Board of Medical Specialties as having the 
secondary subspecialty of Advanced HF and Transplant Cardiology10, 11 or the Heart Failure 
Association of the European Society of Cardiology HF curriculum,12 which is a programme 
designed to last 2 years, and in the second year possible to choose between four different modules 
of which one is specific for HT and mechanical circulatory support. The development in some 
countries of quality standards that define units of advanced HF is an important step forward to 
improve the quality of care of these patients.13, 14 A possible collateral advantage of screening 
for HT and LVAD candidates might be the reinforcement of procedures for referral to such units 
from centres that lack them.13, 15, 16 
 
The reason for wishing to perform HT or LVAD implantation as soon as advancing HF makes 
the patient a candidate is of course that the patient's condition may otherwise deteriorate so quickly 
(i.e. end‐organ damage, particularly liver, kidney or lung) that these therapies become 
contraindicated. It should not be forgotten that the contrary can also occur: it is not unknown for a 
patient listed for HT to improve to the point of having to be removed from the list. Also, the 
condition of a patient for whom HT or LVAD implantation is indicated may, over time, evolve to 
make the other therapy more suitable; and an LVAD implanted as a bridge to transplant may 
eventually be seen as the more appropriate destination therapy, or vice versa.6, 17 Thus, screening 
for HT and LVAD implantation candidates should certainly not determine subsequent therapy 
irrevocably. Lund et al. have nevertheless shown convincingly that such screening definitely has a 
place in the future care of HF patients. It is to be hoped that, by promoting a vision of HT and 
LVAD implantation, not as interventions to be performed only in extremis, but as rather more 
routine procedures, it may also help overturn Lund et al.'s other crushing result: the rejection of 
these therapies by half the patients to whom they were offered.  
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